Semaglutide, a weight reduction medicine, didn’t enhance the chance of depressive signs, suicidal ideas, or suicidal conduct.
The brand new examine was led by researchers from the College of Pennsylvania’s Perelman Faculty of Medication and revealed this week in JAMA Inner Medication (1✔ ✔Trusted Supply
Penn examine finds taking semaglutide for weight administration doesn’t enhance danger of melancholy or suicidal conduct in folks with out recognized main psychopathology
Go to supply
).
The European Medicines Company (EMA) and the Meals and Drug Administration (FDA) are constantly checking on the psychiatric security of semaglutide and associated medication after post-marketing surveillance studies of suicidal conduct, melancholy, and ideas in sufferers taking the medication to deal with weight problems or kind 2 diabetes.
Commercial
Position of Semaglutide in Weight problems Remedy
Semaglutide has emerged as a major development within the discipline of weight administration. The medicine, which was first created as a sort 2 diabetes remedy, obtained lots of consideration after medical trials confirmed that it decreased baseline physique weight by 10% to fifteen%.
These medicines are weekly injections which might be turning into extra widespread for medical professionals to suggest to their sufferers. In 2023, semaglutide was prescribed to just about 5 million Individuals, of whom roughly 4 out of 10 took it for weight administration.
The brand new examine, led by Thomas Wadden, PhD, a professor of Psychology in Psychiatry and the previous director of Penn’s Middle for Weight and Consuming Problems, analyzed information from over 3,500 contributors throughout 4 main medical trials. Researchers examined information from the Semaglutide Remedy Impact in Folks with Weight problems (STEP) trials – STEP 1, 2, 3, and 5. These research had been essential in gaining approval from the FDA to make use of semaglutide 2.4 mg for weight problems.
Commercial
Psychological Well being Issues in Semaglutide Use
The STEP trials present sturdy proof that semaglutide 2.4 mg reduces physique weight and improves quite a few well being problems related to weight problems. Nonetheless, additional examine is required on the psychiatric security of semaglutide 2.4 mg when utilized by individuals with present main depressive dysfunction, different critical psychological sickness (akin to schizophrenia), or a historical past of suicide makes an attempt. People with such circumstances weren’t included within the STEP trials.
The examine examined adjustments in depressive signs utilizing the Affected person Well being Questionnaire-9 (PHQ-9) and assessed suicidal ideation and conduct utilizing the Columbia Suicide Severity Ranking Scale.
Throughout the 68-week STEP 1-3 trials, semaglutide-treated contributors, as in comparison with those that obtained a placebo, didn’t present an elevated danger of creating reasonably extreme signs of melancholy or suicidal ideas or conduct. Related findings had been noticed within the 104-week STEP 5 examine.
Commercial
Despair and Suicidal Ideas with Semaglutide
Inspecting all 4 STEP trials, researchers discovered that 1% or fewer of contributors reported suicidal ideation or conduct throughout remedy, with no variations between semaglutide 2.4 mg and placebo. Furthermore, solely 2.8% of the semaglutide-treated contributors, versus 4.1% of those that obtained placebo, reported ranges of melancholy sooner or later throughout remedy that required analysis by a psychological well being skilled.
These charges are in step with the chance of great melancholy within the common inhabitants. “It’s definitely attainable that people with chubby or weight problems who take semaglutide could expertise depressive signs or suicidal ideation or conduct, however the information recommend that individuals not taking semaglutide – within the placebo group on this examine – are equally more likely to expertise these circumstances,” mentioned Gregory Brown, PhD, a examine co-author and Director of the Penn Middle for the Prevention of Suicide on the Perelman Faculty of Medication.
Wadden and Brown famous that their examine’s findings for semaglutide are in step with outcomes of the FDA’s most up-to-date evaluation of post-marketing surveillance information for this class of medicines which didn’t discover “proof that use of those medicines causes suicidal ideas or actions.”
Reference:
- Penn examine finds taking semaglutide for weight administration doesn’t enhance danger of melancholy or suicidal conduct in folks with out recognized main psychopathology – (https:www.pennmedicine.org/information/news-releases/2024/september/semaglutide-and-mental-health#:~:textual content=PHILADELPHIApercentE2percent80percent94percent20Takingpercent20thepercent20weightpercent20loss,atpercent20thepercent20Universitypercent20ofpercent20Pennsylvania)
Supply-Eurekalert